HOOKIPA Pharma to Present at Upcoming Investor Conferences in September
August 29 2019 - 8:30AM
HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing
a new class of immunotherapeutics targeting infectious diseases and
cancers based on its proprietary arenavirus platform, today
announced that HOOKIPA’s management team will present and host
one-on-one meetings at the following investor conferences in
September:
- Wells Fargo Healthcare Conference 2019 in Boston, on Wednesday,
September 4, 2019 at 4:10 p.m. ET
- 26th Annual NewsMakers in the Biotech Industry in New York, on
Friday, September 6, 2019 at 9:40 a.m. ET
- Bank of America Merrill Lynch Global Healthcare Conference 2019
in London, on Thursday, September 12, 2019
A live audio webcast of the presentation held at the Wells Fargo
Healthcare Conference will be available within the Investors &
Media section of HOOKIPA’s website at
https://ir.hookipapharma.com/events. An archived replay will be
accessible for 30 days following the event.
About
HOOKIPAHOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical
stage biopharmaceutical company developing a new class of
immunotherapeutics, targeting infectious diseases and cancers based
on its proprietary arenavirus platform that is designed to
reprogram the body’s immune system.
HOOKIPA’s proprietary arenavirus-based
technologies, VaxWave®*, a replication-deficient viral vector, and
TheraT®*, a replication-attenuated viral vector, are designed to
induce robust antigen specific CD8+ T cells and
pathogen-neutralizing antibodies. Both technologies are designed to
allow for repeat administration while maintaining an immune
response. TheraT® has the potential to induce CD8+ T cell response
levels previously not achieved by other published immuno-therapy
approaches. HOOKIPA’s “off-the-shelf” viral vectors target
dendritic cells in vivo to activate the immune system.
HOOKIPA’s VaxWave®-based prophylactic
cytomegalovirus vaccine candidate is currently in a Phase 2
clinical trial in patients awaiting kidney transplantation from
living cytomegalovirus-positive donors. To expand its infectious
disease portfolio, HOOKIPA has entered into a collaboration and
licensing agreement with Gilead Sciences, Inc. to jointly research
and develop functional cures for HIV and Hepatitis B infections.
HOOKIPA is building a proprietary immuno-oncology pipeline by
targeting virally mediated cancer antigens, self-antigens and
next-generation antigens.
TheraT® and VaxWave® are not approved anywhere
globally and their safety and efficacy have not been
established.
Find out more about HOOKIPA online at
www.hookipapharma.com.
*Registered in Europe; Pending in the US.
For further information, please contact:
MediaNina Waibel Senior Director -
Communications Nina.Waibel@HookipaPharma.com
InvestorsMatt BeckExecutive Director - Investor
RelationsMatthew.Beck@HookipaPharma.com
Media enquiries Sue Charles/ Ashley Tapp
Instinctif Partners Hookipa@Instinctif.com +44 (0)20 7457 2020
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Mar 2024 to Apr 2024
HOOKIPA Pharma (NASDAQ:HOOK)
Historical Stock Chart
From Apr 2023 to Apr 2024